MedImmune Appoints Development Leadership Team
This article was originally published in The Pink Sheet Daily
Former Cambridge Antibody Technology exec to oversee product development.
You may also be interested in...
MedImmune, which absorbs Cambridge Antibody Technologies, will continue to operate independently from AstraZeneca.
Deal for Cambridge Antibody Technology, valued at $1.07 bil., will shift focus of AstraZeneca’s pipeline.
United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.